Exact Sciences Past Earnings Performance
Past criteria checks 0/6
Exact Sciences's earnings have been declining at an average annual rate of -2.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 22.2% per year.
Key information
-2.5%
Earnings growth rate
2.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 22.2% |
Return on equity | -5.5% |
Net Margin | -6.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Exact Sciences: Cost Optimization And Product Strength
Aug 18Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Aug 14Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued
Jan 10Revenue & Expenses Breakdown
How Exact Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2,612 | -175 | 1,645 | 458 |
31 Mar 24 | 2,535 | -240 | 1,655 | 441 |
31 Dec 23 | 2,500 | -204 | 1,638 | 426 |
30 Sep 23 | 2,406 | -282 | 1,625 | 405 |
30 Jun 23 | 2,301 | -432 | 1,612 | 385 |
31 Mar 23 | 2,200 | -517 | 1,624 | 387 |
31 Dec 22 | 2,084 | -624 | 1,640 | 393 |
30 Sep 22 | 2,005 | -716 | 1,695 | 388 |
30 Jun 22 | 1,938 | -735 | 1,682 | 372 |
31 Mar 22 | 1,852 | -745 | 1,609 | 372 |
31 Dec 21 | 1,767 | -596 | 1,538 | 386 |
30 Sep 21 | 1,760 | -793 | 1,370 | 744 |
30 Jun 21 | 1,712 | -829 | 1,249 | 700 |
31 Mar 21 | 1,546 | -720 | 1,126 | 626 |
31 Dec 20 | 1,491 | -824 | 1,071 | 554 |
30 Sep 20 | 1,321 | -327 | 961 | 151 |
30 Jun 20 | 1,131 | -165 | 875 | 154 |
31 Mar 20 | 1,062 | -136 | 802 | 151 |
31 Dec 19 | 876 | -213 | 738 | 140 |
30 Sep 19 | 724 | -216 | 606 | 116 |
30 Jun 19 | 623 | -221 | 551 | 99 |
31 Mar 19 | 526 | -219 | 493 | 84 |
31 Dec 18 | 454 | -175 | 427 | 67 |
30 Sep 18 | 399 | -143 | 369 | 60 |
30 Jun 18 | 353 | -124 | 326 | 54 |
31 Mar 18 | 308 | -119 | 293 | 49 |
31 Dec 17 | 266 | -114 | 263 | 42 |
30 Sep 17 | 214 | -130 | 241 | 37 |
30 Jun 17 | 169 | -141 | 219 | 32 |
31 Mar 17 | 133 | -155 | 205 | 31 |
31 Dec 16 | 99 | -167 | 190 | 33 |
30 Sep 16 | 79 | -170 | 176 | 36 |
30 Jun 16 | 63 | -175 | 167 | 38 |
31 Mar 16 | 50 | -169 | 154 | 37 |
31 Dec 15 | 39 | -158 | 140 | 34 |
30 Sep 15 | 27 | -150 | 128 | 30 |
30 Jun 15 | 14 | -139 | 112 | 28 |
31 Mar 15 | 6 | -120 | 90 | 27 |
31 Dec 14 | 2 | -100 | 69 | 29 |
30 Sep 14 | 1 | -80 | 51 | 30 |
30 Jun 14 | 2 | -59 | 33 | 28 |
31 Mar 14 | 3 | -52 | 28 | 28 |
31 Dec 13 | 4 | -47 | 24 | 27 |
30 Sep 13 | 4 | -48 | 21 | 31 |
Quality Earnings: EXAS is currently unprofitable.
Growing Profit Margin: EXAS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EXAS is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: EXAS has a negative Return on Equity (-5.48%), as it is currently unprofitable.